AI-generated summary
This review summarizes current knowledge on detecting and treating medication-related osteonecrosis of the jaw, a serious side effect of antiresorptive and antiangiogenic drugs such as bisphosphonates. The authors report that prevention and treatment efficacy remain limited, possibly because the underlying pathomechanism is incompletely understood. They emphasize interdisciplinary cooperation and careful monitoring to reduce this iatrogenic complication.
- Who or what was studied
- Patients receiving antiresorptive or antiangiogenic drugs, such as bisphosphonates, who may develop medication-related osteonecrosis of the jaw
- Limits stated in the abstract
- The abstract describes a literature-based review and states that the pathomechanism is incompletely understood, so prevention and treatment options are limited.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on akjournals.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.